MHLW Panel Clears Approval Path For Vidaza, Direct Competitor To Eisai's Dacogen
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Kitasato Institute Research Center for Biologicals' freeze-dried rubella and measles vaccine and Nippon Shinyaku's Vidaza (azacitidine) for myelodysplastic syndromes were recommended for approval by the Ministry of Health, Labor and Welfare's Pharmaceutical and Food Sanitation Council's Second Pharmaceutical Subcommittee, an official of the bureau's Examination and Administration Division confirmed
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)